Nath Bio-Genes (India) Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Satish Kagliwal
Algemeen directeur
₹6.6m
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 25.2yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 6.3yrs |
| Gemiddelde ambtstermijn bestuur | 3.9yrs |
Recente managementupdates
Recent updates
Here's Why Shareholders Should Examine Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) CEO Compensation Package More Closely
Aug 11
Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Solid Earnings May Rest On Weak Foundations
Jul 31Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Shares Fly 34% But Investors Aren't Buying For Growth
Jul 02These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Jun 27Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has More To Do To Multiply In Value Going Forward
Apr 05Returns On Capital At Nath Bio-Genes (India) (NSE:NATHBIOGEN) Have Hit The Brakes
Oct 24Nath Bio-Genes (India) (NSE:NATHBIOGEN) Seems To Use Debt Quite Sensibly
Aug 05Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has Some Way To Go To Become A Multi-Bagger
Jun 07Some Investors May Be Worried About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Feb 11We Think Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Taking Some Risk With Its Debt
Aug 27Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital Not Reflecting Well On The Business
Jun 19Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has A Pretty Healthy Balance Sheet
Feb 24Returns On Capital Signal Tricky Times Ahead For Nath Bio-Genes (India) (NSE:NATHBIOGEN)
May 27Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Feb 28The Trends At Nath Bio-Genes (India) (NSE:NATHBIOGEN) That You Should Know About
Feb 07Declining Stock and Decent Financials: Is The Market Wrong About Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)?
Jan 19The Nath Bio-Genes (India) (NSE:NATHBIOGEN) Share Price Is Up 149% And Shareholders Are Boasting About It
Jan 01Why Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay Matters
Dec 14
These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Nov 26Here's What To Make Of Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Nov 05Do Its Financials Have Any Role To Play In Driving Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) Stock Up Recently?
Oct 15Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Might Not Be As Mispriced As It Looks After Plunging 25%
Sep 24Many Still Looking Away From Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
Sep 08Introducing Nath Bio-Genes (India) (NSE:NATHBIOGEN), The Stock That Soared 311% In The Last Five Years
Sep 07Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Doing What It Can To Lift Shares
Aug 18Here's What We Think About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay
Jul 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹394m |
| Jun 30 2024 | n/a | n/a | ₹398m |
| Mar 31 2024 | ₹7m | ₹7m | ₹396m |
| Dec 31 2023 | n/a | n/a | ₹374m |
| Sep 30 2023 | n/a | n/a | ₹379m |
| Jun 30 2023 | n/a | n/a | ₹374m |
| Mar 31 2023 | ₹5m | ₹5m | ₹350m |
| Dec 31 2022 | n/a | n/a | -₹827m |
| Sep 30 2022 | n/a | n/a | -₹813m |
| Jun 30 2022 | n/a | n/a | -₹815m |
| Mar 31 2022 | ₹5m | ₹5m | -₹674m |
| Dec 31 2021 | n/a | n/a | ₹561m |
| Sep 30 2021 | n/a | n/a | ₹575m |
| Jun 30 2021 | n/a | n/a | ₹593m |
| Mar 31 2021 | ₹5m | ₹5m | ₹557m |
| Dec 31 2020 | n/a | n/a | ₹562m |
| Sep 30 2020 | n/a | n/a | ₹558m |
| Jun 30 2020 | n/a | n/a | ₹565m |
| Mar 31 2020 | ₹5m | ₹5m | ₹505m |
| Dec 31 2019 | n/a | n/a | ₹482m |
| Sep 30 2019 | n/a | n/a | ₹478m |
| Jun 30 2019 | n/a | n/a | ₹477m |
| Mar 31 2019 | ₹5m | ₹5m | ₹384m |
| Dec 31 2018 | n/a | n/a | ₹349m |
| Sep 30 2018 | n/a | n/a | ₹353m |
| Jun 30 2018 | n/a | n/a | ₹353m |
| Mar 31 2018 | ₹3m | ₹3m | ₹294m |
Compensatie versus markt: De totale vergoeding ($USD 78.49K ) Satish } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.82K ).
Compensatie versus inkomsten: De vergoeding van Satish is het afgelopen jaar met meer dan 20% gestegen.
CEO
Satish Kagliwal (67 yo)
25.2yrs
Tenure
₹6,600,000
Compensatie
Mr. Satish Kagliwal serves as the Chairman of the Board at Agri-tech (India) Limited and has been its Executive Director since August 30, 1999 & serves as it's Managing Director of Agri-tech (India) Limite...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹6.60m | geen gegevens | |
| Company Secretary & Compliance Officer | 6.3yrs | ₹844.00k | geen gegevens | |
| Vice President of Marketing | no data | ₹7.99m | geen gegevens | |
| Executive Director | no data | ₹20.00k | 0.0015% ₹ 55.0k | |
| Chief People Officer | no data | ₹4.14m | geen gegevens | |
| Vice President of R&D | 6.3yrs | ₹10.07m | geen gegevens | |
| Chief Financial Officer | no data | geen gegevens | geen gegevens |
6.3yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NATHBIOGEN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 25.2yrs | ₹6.60m | geen gegevens | |
| Executive Director | 5.4yrs | ₹20.00k | 0.0015% ₹ 55.0k | |
| Non-Executive Director | 1.5yrs | ₹15.00k | geen gegevens | |
| Independent Non-Executive Director | 2.6yrs | ₹20.00k | geen gegevens | |
| Independent Non-Executive Director | 4yrs | ₹20.00k | geen gegevens | |
| Independent Non-Executive Director | 3.9yrs | ₹23.00k | geen gegevens | |
| Independent Non-Executive Director | 3.7yrs | ₹23.00k | geen gegevens |
3.9yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NATHBIOGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).